CompaniesGemini Therapeutics

Gemini Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

MergedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

3

As Collaborator

0

Total Enrollment

124

By Phase

PHASE2: 2PHASE1: 1

By Status

TERMINATED: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
Today
NCT04643886
NCT04684394
Hover over trial bars to see details

Recent Trials

NCT04684394Lead Sponsor
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
PHASE2Terminated
50 participants
Started: Dec 29, 2020 · Completed: Feb 18, 2022
NCT04643886Lead Sponsor
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
PHASE2Terminated
62 participants
Started: Jul 30, 2020 · Completed: Mar 21, 2022
NCT04246866Lead Sponsor
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
PHASE1Completed
12 participants
Started: Dec 19, 2019 · Completed: Oct 21, 2020
Funding History (1)
D
May 2, 2016
Filing
Related Companies
Disc Medicine
merged